Innovent boasts another pivotal trial success for obesity drug
High-dose Xinermei has shown success in the GLORY-2 trial, teeing it up for approval in obesity in China.
21 November 2025
21 November 2025
High-dose Xinermei has shown success in the GLORY-2 trial, teeing it up for approval in obesity in China.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.